Comparison of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging for locally advanced breast cancer staging: A prospective study from a tertiary hospital cancer centre in the Western Cape

SA Journal of Oncology


 
 
Field Value
 
Title Comparison of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging for locally advanced breast cancer staging: A prospective study from a tertiary hospital cancer centre in the Western Cape
 
Creator Chilwesa, Paul M. Gameldien, Rufkah Steyn, Rachelle More, Stuart Malherbe, Francois Human, Gercios Mottay, Lynelle Moxley, Karis Hardy, Anneli Anderson, David Hunter, Alistair J. Parkes, Jeannette
 
Subject — locally advanced breast cancer; NACT; 18F-FDG PET/CT; conventional imaging; staging; South Africa; LMICs
Description Background: Breast cancer is the second most common cancer in adults and the most frequent cancer diagnosed in women. In South Africa, breast cancer accounts for 38.5% of cancers diagnosed in women. Since the presence, extent and location of distant metastases is one important prognostic factor in locally advanced breast cancer (LABC), accurate staging at diagnosis is crucial to ensure that patients receive the appropriate treatment. Increasing evidence shows that the use of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for disease staging of LABC may improve diagnostic sensitivity.Aim: The aim of this study was to prospectively assess the difference in diagnostic accuracy between whole-body PET/PET-CT and conventional imaging (CI) for staging LABC.Setting: The breast cancer outpatient clinic at Groote Schuur Hospital in Cape Town, South Africa.Methods: A total of 42 participants with clinical stage III and a select few stage II breast cancer underwent both 18F-FDG PET/CT and CI.Results: The 18F-FDG PET/CT found significantly more (p = 0.0077) distant metastatic sites than CI (36% vs. 21%). The 18F-FDG PET/CT upstaged 9 (21.4%) of patients from clinical stage IIIa to stage IIIc, and changed in management of 54% of patients. Thirty-eight per cent of the patients had their clinical stage unchanged. One of five suspected metastatic sites 18F FDG PET/CT on biopsy was positive for malignancy.Conclusion: The 18F-FDG PET/CT is useful for staging locally advanced non-inflammatory infiltrating ductal carcinoma of the breast. Use of 18F-FDG PET/CT was superior to conventional imaging in assessing metastatic mediastinal lymphadenopathy, but with a poor specificity. The use of 18F-FDG PET/CT in LABC is useful, with the biopsy of isolated suspicious lesions for metastasis increasing its accuracy.
 
Publisher AOSIS
 
Contributor
Date 2020-09-10
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — —
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajo.v4i0.106
 
Source South African Journal of Oncology; Vol 4 (2020); 8 pages 2523-0646 2518-8704
 
Language eng
 
Relation https://sajo.org.za/index.php/sajo/article/view/106/373 https://sajo.org.za/index.php/sajo/article/view/106/372 https://sajo.org.za/index.php/sajo/article/view/106/374 https://sajo.org.za/index.php/sajo/article/view/106/371
 
Coverage — — —
Rights Copyright (c) 2020 Paul M. Chilwesa, Rufkah Gameldien, Rachelle Steyn, Stuart More, Francois Malherbe, Gercios Human, Lynelle Mottay, Karis Moxley, Anneli Hardy, David Anderson, Alistair J. Hunter, Jeannette Parkes https://creativecommons.org/licenses/by/4.0